Indivior Pharmaceuticals, Inc. (INDV)

34.87 -1.22% (-0.43)

Over 6M: +9.0%

2026-08-28
30 35 40
Mar Apr May Jun Jul Aug

Financials Quarterly

Q1 '24 — Revenue: 284M Q1 '24 — Operating Cash Flow: -37M Q1 '24 — Free Cash Flow: -39M Q1 '24 — Net Income: 61M Q2 '24 — Revenue: 299M Q2 '24 — Operating Cash Flow: 88M Q2 '24 — Free Cash Flow: 84M Q2 '24 — Net Income: -97M Q3 '24 — Revenue: 307M Q3 '24 — Operating Cash Flow: 2M Q3 '24 — Free Cash Flow: -5M Q3 '24 — Net Income: 22M Q4 '24 — Revenue: 299M Q4 '24 — Operating Cash Flow: -17M Q4 '24 — Free Cash Flow: -33M Q4 '24 — Net Income: 21M Q1 '25 — Revenue: 266M Q1 '25 — Operating Cash Flow: 75M Q1 '25 — Free Cash Flow: 70M Q1 '25 — Net Income: 47M Q2 '25 — Revenue: 302M Q2 '25 — Operating Cash Flow: 158M Q2 '25 — Free Cash Flow: 141M Q2 '25 — Net Income: 18M Q3 '25 — Revenue: 314M Q3 '25 — Operating Cash Flow: -39M Q3 '25 — Free Cash Flow: -59M Q3 '25 — Net Income: 42M Q4 '25 — Revenue: 358M Q4 '25 — Operating Cash Flow: -221M Q4 '25 — Free Cash Flow: -245M Q4 '25 — Net Income: 102M Q1 '26 — Revenue: 317M Q1 '26 — Operating Cash Flow: -9M Q1 '26 — Free Cash Flow: -29M Q1 '26 — Net Income: 89M Q2 '26 — Revenue: 343M Q2 '26 — Operating Cash Flow: 229M Q2 '26 — Free Cash Flow: 222M Q2 '26 — Net Income: 122M -150M 0 150M 300M 450M
Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

7.2
ROIC 583.5%
Oper. margin 31.6%
OE margin -10.7%
Gross margin 82.1%
ROA 28.8%
ROCE 115.3%
Accruals 32.0%
FCF margin -8.3%
OCF / EBIT -0.095×
OCF margin -3.0%
ROE —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

5.5
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

5.3
ND/EBITDA —
Current ratio 0.84×
Payout 0.0%
Cash / Debt 0.46×
Quick ratio 0.66×
F-score 4.0 pts
Cash runway —
Debt / Eq —
Debt payback —
Equity / Assets —
Net debt / Eq —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

6.0
Sales/sh Y/Y +17.9%
Sales CAGR 4Y +11.9%
EBIT Y/Y +92.2%
EPS Y/Y +241.6%
Sales Q/Q +13.6%
Div. growth —
EBIT CAGR —
EPS CAGR 4Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.